Monthly archive
22 carefully sourced stories published during this month.
Latest GLP-1 news30 August 2026
The FDA has expanded Mounjaro’s US label to include major cardiovascular risk reduction in high-risk adults with type 2 diabetes. We explain the SURPASS-CVOT evidence and its limits.
Read the sourced summary30 August 2026
Roche’s Genentech has licensed HM17321 in a deal potentially worth $2.3 billion. We examine the conditional economics, UCN2 mechanism and early evidence behind its muscle-preservation aim.
Read the sourced summary27 August 2026
A matched US claims study linked sustained tirzepatide use after age 55 with lower hospital and emergency-care spending. We examine the estimates, methods and important cost caveat.
Read the sourced summary21 August 2026
A randomized Phase II trial reported up to 9.7% average weight reduction with oral VCT220 at 16 weeks. We examine the dose response, titration, gastrointestinal effects and limitations.
Read the sourced summary20 August 2026
A 725-person Phase 3 trial reported greater average weight loss with survodutide than placebo at 76 weeks. We examine both analysis methods, tolerability and what remains unknown.
Read the sourced summary19 August 2026
A randomized trial and newer analyses raise an important question: are semaglutide's cardiovascular effects fully explained by weight loss? Here is what is established and what remains uncertain.
Read the sourced summary17 August 2026
Two systematic reviews found substantial average weight regain after GLP-1 treatment stopped. We examine the 60% estimate, longer-term projections and what remains unknown.
Read the sourced summary16 August 2026
In REIMAGINE 1, CagriSema reduced average HbA1c by up to 1.8 percentage points and body weight by 13.8% at 40 weeks. We examine the results, gastrointestinal effects and limitations.
Read the sourced summary14 August 2026
A peer-reviewed Phase 2b trial reported up to 12.1% average weight loss with daily aleniglipron at 36 weeks. We examine the design, tolerability and why Phase 3 evidence is still needed.
Read the sourced summary13 August 2026
Blood samples from 2,970 older SELECT participants produced a more favourable proteomic dementia-risk score with semaglutide. We explain why that is intriguing but not evidence of prevention.
Read the sourced summary12 August 2026
A US Veterans Affairs Phase 3 trial plans to enrol 622 veterans across 19 currently listed sites. We explain what it will measure, why earlier trials are encouraging and what remains unknown.
Read the sourced summary11 August 2026
A 2026 multicentre study reported 16.6% average weight loss with tirzepatide and 13.4% with semaglutide at 12 months. We examine the findings, the side-effect figures and the limits of real-world evidence.
Read the sourced summary10 August 2026
The FDA has received hundreds of reports associated with compounded semaglutide and tirzepatide, while UK regulators are tackling fake pens and illegal manufacturing. Here is what each category means and what the figures cannot prove.
Read the sourced summary9 August 2026
A UK headline reported more than 150 deaths after GLP-1 drug use. We checked the MHRA Yellow Card profiles and found important distinctions between reports, reactions, fatal outcomes and proved causation.
Read the sourced summary8 August 2026
The MHRA has strengthened pancreatitis warnings for GLP-1 and dual GIP/GLP-1 medicines after 1,296 UK Yellow Card reports. Here is what the figures show, what they cannot establish and which symptoms require urgent attention.
Read the sourced summary7 August 2026
Wegovy tablets and Foundayo are both oral weight-management medicines, but their ingredients and routines differ. We explain how pills, injections, multi-agonists and new indications are creating a more complex treatment ecosystem.
Read the sourced summary6 August 2026
A 157,880-person study linked GLP-1 use with a lower rate of age-related macular degeneration. We examine the result, conflicting evidence and the difference between association and prevention.
Read the sourced summary5 August 2026
We verify the oral GLP-1 shift and compare four closely watched successors without treating company topline results, cross-trial percentages or Phase 3 status as proof of superiority.
Read the sourced summary4 August 2026
‘Whole-body medicine’ is useful industry shorthand, not a medical category. We rank the evidence across cardiovascular disease, MASH, kidney disease, asthma, addiction and Alzheimer’s.
Read the sourced summary4 August 2026
We separate Novo Nordisk’s approved oral Wegovy launch from its investigational zenagamtide programme and explain why changing treatment formats makes accurate medication history more valuable.
Read the sourced summary3 August 2026
We examine the anatomy behind apparent changes in penile length, the unsupported 1–2 inch claim, and conflicting evidence about semaglutide and erectile function.
Read the sourced summary2 August 2026
GLP-1 and related medicines now have defined cardiovascular, kidney, MASH and sleep-apnoea uses. We separate those approvals from early research and a negative Alzheimer’s programme.
Read the sourced summaryEvery published evidence summary remains available in the archive.
